The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s chickenpox vaccine market report forecasts the chickenpox vaccine market size to grow to $4.20 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Chickenpox Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Chickenpox Vaccine Market Size Forecast
The global chickenpox vaccine market is expected to grow from $3.15 billion in 2022 to $3.35 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The chickenpox vaccine market size is expected to grow to $4.20 billion in 2027 at a CAGR of 5.8%.

North America held the largest chickenpox vaccine market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Chickenpox Vaccine Market Driver ­– Rise In The Prevalence Of Chickenpox Disease
For instance, in April 2021, according to a report published by the Centers for Disease Control and Prevention (CDC), a US-based international public health agency, in the USA, around 4 million people have chickenpox annually, and over 10, 500 of them end up in hospitals, and between 100 and 150 of them pass away. Therefore, the rising prevalence of chickenpox disease is driving the growth of the chickenpox vaccine market.

Request for A Sample Of The Global Chickenpox Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

Key Chickenpox Vaccine Market Trend – Developing Novel Drug Developments
Major companies operating in the market are developing novel drugs with improved efficacy, innovative derivatives, and others to sustain their position in the market. For instance, in November 2022, Sinovac Biotech Ltd., a China-based company focused on research, development, and manufacturing of vaccines, stated that the World Health Organization (WHO) granted it prequalification for its live attenuated chickenpox (varicella) vaccine, which is the world’s first varicella vaccine to receive prequalification. The Oka strain is the source of the varicella vaccine, which is produced in the exclusive Human Diploid Cell (SV-1 strain) of SINOVAC. This cell is created by cultivating and harvesting the virus, adding stabilizers, and freeze-drying it. A phase III efficacy trial found that the seroconversion rate of the vaccine-embedded children group, aged 1 to 12 years old, was 97.1%; the vaccine’s efficacy against varicella and against breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine offers 100 percent defense against mild and serious conditions.

Chickenpox Vaccine Market Segment
1) By Vaccine: Monovalent varicella vaccine, Combination varicella vaccine
2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination
3) By End-Users: Hospitals, Clinics, Other End-Users

Chickenpox Vaccine Market Major Players and Strategies
Major players in the chickenpox vaccine market are Bio-Med, GSK plc., Novo Medi Sciences Pvt. Ltd., Takeda Pharmaceutical Company Limited, Green Cross Corporation, Merck & Co Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Novartis AG, AstraZeneca plc., Emergent BioSolutions Inc., Daiichi Sankyo Company Limited, Zydus Lifesciences Limited, Sinovac Biotech Ltd., and GC Biopharma Corp.

In July 2022, GC LabCell, a South Korea-based biotechnology company signed a definitive merger agreement with GC Cell Corporation, a South Korea-based biotechnology company operating in chickenpox vaccine. The transaction brings together two leading South Korean biopharmaceutical businesses with highly complementary portfolios, a robust wide cell therapy R&D pipeline, and cutting-edge manufacturing capabilities to accelerate growth and boost wealth generation.

The Chickenpox Vaccine Global Market Report 2023 covers regional data on chickenpox vaccine market size, chickenpox vaccine market trends and drivers, opportunities, strategies, and chickenpox vaccine market competitor analysis. The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Chickenpox vaccines are biological preparations that stimulate the cell-mediated immune response and prepare it to fight future infections caused by viruses by triggering IgG-mediated production of antibodies against varicella-zoster-specific pathogens that enter the body. The varicella-zoster virus causes chickenpox, which is a highly contagious disease (VZV).

View More Reports Related To The Chickenpox Vaccine Market –
DTP Vaccines Global Market Report 2023
Pediatric Vaccine Global Market Report 2023
H1N1 Vaccine Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: